NASDAQ:ANIX Anixa Biosciences (ANIX) Stock Price, News & Analysis $2.78 0.00 (0.00%) As of 09/25/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Anixa Biosciences Stock (NASDAQ:ANIX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Anixa Biosciences alerts:Sign Up Key Stats Today's Range$2.69▼$2.8750-Day Range$2.60▼$3.7552-Week Range$2.32▼$5.46Volume355,786 shsAverage Volume362,118 shsMarket Capitalization$96.63 millionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingHold Company Overview Anixa Biosciences, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and infectious diseases. The company’s research programs are designed to use the immune system to prevent or treat serious illnesses. Anixa’s cancer programs include vaccine approaches for ovarian cancer and triple-negative breast cancer, developed in collaboration with researchers at Cleveland Clinic. The company is also developing chimeric antigen receptor T-cell, or CAR-T, therapies intended to target cancer cells, including programs focused on ovarian cancer. In addition to oncology, Anixa has pursued vaccine and therapeutic technologies for infectious diseases. The company is headquartered in San Jose, California, and is led by Chief Executive Officer Amit Kumar. Anixa was formerly known as ITUS Corporation before adopting its current name in 2018.AI Generated. May Contain Errors. Read More Anixa Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks77th Percentile Overall ScoreANIX MarketRank™: Anixa Biosciences scored higher than 77% of companies evaluated by MarketBeat, and ranked 194th out of 908 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingHold Consensus RatingAnixa Biosciences has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialAnixa Biosciences has a consensus price target of $8.00, representing about 187.8% upside from its current price of $2.78.Amount of Analyst CoverageAnixa Biosciences has only been the subject of 4 research reports in the past 90 days.Read more about Anixa Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Earnings GrowthEarnings for Anixa Biosciences are expected to remain at ($0.31) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Anixa Biosciences is -8.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anixa Biosciences is -8.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnixa Biosciences has a P/B Ratio of 7.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.12% of the float of Anixa Biosciences has been sold short.Short Interest Ratio / Days to CoverAnixa Biosciences has a short interest ratio ("days to cover") of 2.72, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Anixa Biosciences has recently increased by 6.22%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAnixa Biosciences does not currently pay a dividend.Dividend GrowthAnixa Biosciences does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.31 News SentimentAnixa Biosciences has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Anixa Biosciences this week, compared to 3 articles on an average week.Search InterestOnly 6 people have searched for ANIX on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.MarketBeat Follows12 people have added Anixa Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership4.6 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of Anixa Biosciences in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $270,240.00 in company stock, which represents 0.2797% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Anixa Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $270,240.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders26.40% of the stock of Anixa Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions29.13% of the stock of Anixa Biosciences is held by institutions.Read more about Anixa Biosciences' insider trading history. Receive ANIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anixa Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ANIX Stock News HeadlinesAnixa Biosciences (NASDAQ:ANIX) Director Lewis Titterton, Jr. Acquires 49,036 Shares of Company Stock35 minutes ago | insidertrades.comH.C. Wainwright下调Anixa Biosciences目标股价至$6September 23 at 3:39 PM | cn.investing.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.September 26 at 1:00 AM | Behind the Markets (Ad)Anixa Secures Australia Patent Covering Breast Cancer Vaccine Through 2040September 21, 2026 | rttnews.comAnixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040September 21, 2026 | prnewswire.comAnixa Biosciences Appoints UPenn's Dr. Carmen Guerra To Cancer Advisory BoardSeptember 16, 2026 | rttnews.comAnixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory BoardSeptember 16, 2026 | prnewswire.comLewis Titterton, Jr. Purchases 10,000 Shares of Anixa Biosciences (NASDAQ:ANIX) StockSeptember 15, 2026 | insidertrades.comSee More Headlines ANIX Stock Analysis - Frequently Asked Questions How have ANIX shares performed this year? Anixa Biosciences' stock was trading at $3.12 at the beginning of the year. Since then, ANIX shares have decreased by 10.9% and is now trading at $2.78. How were Anixa Biosciences' earnings last quarter? Anixa Biosciences Inc (NASDAQ:ANIX) announced its earnings results on Wednesday, September, 9th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.00. Who are Anixa Biosciences' major shareholders? Top institutional investors of Anixa Biosciences include BlackRock Inc. (0.59%), GSA Capital Partners LLP (0.35%), Bank of New York Mellon Corp (0.14%) and Corient Private Wealth LP (0.11%). Insiders that own company stock include Lewis H Titterton Jr, Amit Kumar, Arnold M Baskies and Michael Catelani. View institutional ownership trends. How do I buy shares of Anixa Biosciences? Shares of ANIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Anixa Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Anixa Biosciences investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Coty (COTY), AbbVie (ABBV), Adverum Biotechnologies (ADVM) and Avino Silver & Gold Mines (ASM). Company Calendar Last Earnings9/09/2026Today9/26/2026Fiscal Year End10/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 ANIX's financial health is in the Green zone, according to TradeSmith. ANIX has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ANIX CIK715446 Webwww.anixa.com Phone(408) 708-9808Fax631-549-5974Employees4Year Founded1982Price Target and Rating Average Price Target for Anixa Biosciences$8.00 High Price Target$10.00 Low Price Target$6.00 Potential Upside/Downside+187.8%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.93 million Net MarginsN/A Pretax MarginN/A Return on Equity-76.59% Return on Assets-67.80% Debt Debt-to-Equity RatioN/A Current Ratio8.55 Quick Ratio8.54 Sales & Book Value Annual Sales$210 thousand Price / Sales460.16 Cash FlowN/A Price / Cash FlowN/A Book Value$0.38 per share Price / Book7.32Miscellaneous Outstanding Shares34,760,000Free Float25,586,000Market Cap$96.63 million OptionableOptionable Beta0.51 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:ANIX) was last updated on 9/26/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...Stansberry Research | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going t...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anixa Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Anixa Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
